Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence by Dupont, Annabelle et al.
HAL Id: hal-02347340
https://hal.archives-ouvertes.fr/hal-02347340
Submitted on 5 Nov 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Relevance of platelet desialylation and
thrombocytopenia in type 2B von Willebrand disease:
preclinical and clinical evidence
Annabelle Dupont, Christelle Soukaseum, Mathilde Cheptou, Frédéric Adam,
Thomas Nipoti, Marc-Damien Lourenco-Rodrigues, Paulette Legendre,
Valérie Proulle, Antoine Rauch, Charlotte Kawecki, et al.
To cite this version:
Annabelle Dupont, Christelle Soukaseum, Mathilde Cheptou, Frédéric Adam, Thomas Nipoti, et al..
Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclin-
ical and clinical evidence. Haematologica, Ferrata Storti Foundation, 2019, pp.haematol.2018.206250.
￿10.3324/haematol.2018.206250￿. ￿hal-02347340￿
Relevance of platelet desialylation and thrombocytopenia
in type 2B von Willebrand disease: preclinical and clinical
evidence
by Annabelle Dupont, Christelle Soukaseum, Mathilde Cheptou, Frédéric Adam, 
Thomas Nipoti, Marc-Damien Lourenco-Rodrigues, Paulette Legendre, Valérie Proulle, 
Antoine Rauch, Charlotte Kawecki, Marijke Bryckaert, Jean-Philippe Rosa, Camille Paris, 
Catherine Ternisien, Pierre Boisseau, Jenny Goudemand, Delphine Borgel, Dominique Lasne,
Pascal Maurice, Peter J. Lenting, Cécile V. Denis, Sophie Susen, and Alexandre Kauskot 
Haematologica 2019 [Epub ahead of print]
Citation: Annabelle Dupont, Christelle Soukaseum, Mathilde Cheptou, Frédéric Adam, Thomas Nipoti,
Marc-Damien Lourenco-Rodrigues, Paulette Legendre, Valérie Proulle, Antoine Rauch, 
Charlotte Kawecki, Marijke Bryckaert, Jean-Philippe Rosa, Camille Paris, Catherine Ternisien, 
Pierre Boisseau, Jenny Goudemand, Delphine Borgel, Dominique Lasne, Pascal Maurice, 
Peter J. Lenting, Cécile V. Denis, Sophie Susen, and Alexandre Kauskot. Relevance of platelet 
desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence.
Haematologica. 2019; 104:xxx
doi:10.3324/haematol.2018.206250
Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science.
Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that
have completed a regular peer review and have been accepted for publication. E-publishing
of this PDF file has been approved by the authors. After having E-published Ahead of Print,
manuscripts will then undergo technical and English editing, typesetting, proof correction and
be presented for the authors' final approval; the final version of the manuscript will then
appear in print on a regular issue of the journal. All legal disclaimers that apply to the
journal also pertain to this production process.
 Copyright 2019 Ferrata Storti Foundation.
Published Ahead of Print on February 28, 2019, as doi:10.3324/haematol.2018.206250.
 1
Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand 
disease: preclinical and clinical evidence 
 
Annabelle Dupont1,2, Christelle Soukaseum3, Mathilde Cheptou3, Frédéric Adam3, Thomas 
Nipoti3, Marc-Damien Lourenco-Rodrigues3, Paulette Legendre3, Valérie Proulle3,4, Antoine 
Rauch1,2, Charlotte Kawecki3, Marijke Bryckaert3, Jean-Philippe Rosa3, Camille Paris2, 
Catherine Ternisien5, Pierre Boisseau6, Jenny Goudemand1,2, Delphine Borgel3,7, Dominique 
Lasne3,7, Pascal Maurice8, Peter J. Lenting3, Cécile V. Denis3, Sophie Susen1,2,$, Alexandre 
Kauskot3,$ 
 
1 Université de Lille, UMR Inserm 1011, Institut Pasteur de Lille, EGID, F-59000 Lille, France. 
2 Department of Hematology, CHU de Lille, F-59000 Lille, France.  
3 HITh, UMR_S 1176, INSERM Univ. Paris-Sud, Université Paris-Saclay, F-94270 Le 
Kremlin-Bicêtre, France. 
4 AP-HP, Department of Biological Hematology, CHU Bicêtre, Hôpitaux Universitaires Paris 
Sud, F-94270 Paris, France. 
5
 Laboratory of Hematology, CHU de Nantes, F-44000 Nantes, France. 
6 Medical Genetic Department, CHU de Nantes, F-44000 Nantes, France. 
7
 AP-HP, Department of Biological Hematology, Hôpital Necker, F-75015 Paris, France. 
8
 UMR CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), Team 2 
"Matrix aging and Vascular remodelling", Université de Reims Champagne Ardenne (URCA), 
UFR Sciences Exactes et Naturelles, F-51000 Reims, France 
 
$
 contributed equally as senior authors 
 
Running title: Platelet desialylation in type 2B von Willebrand disease 
 
Corresponding author: 
Alexandre Kauskot 
INSERM U1176, Hôpital Kremlin Bicêtre 
80, rue du Général Leclerc 
F-94276 Le Kremlin-Bicêtre cedex 
France 
Phone: + 33-149-595-616 
E-mail: alexandre.kauskot@inserm.fr 
 
Keywords: desialylation, platelet, Willebrand, thrombocytopenia 
 
Word count: 3542 words 
 
Figures: 5 
 
 
 
 2
ABSTRACT 
Patients with type 2B von Willebrand disease (caused by gain-of-function mutations in the 
gene coding for von Willebrand factor) display bleeding to a variable extent and, in some 
cases, thrombocytopenia. There are several underlying causes of thrombocytopenia in type 
2B von Willebrand disease. It was recently suggested that desialylation-mediated platelet 
clearance leads to thrombocytopenia in this disease. However, this hypothesis has not been 
tested in vivo. 
The relationship between platelet desialylation and the platelet count was probed in 36 
patients with type 2B von Willebrand disease (with p.R1341Q, p.R1306Q, and p.V1316M 
mutations) and in a mouse model carrying the severe p.V1316M mutation (the 2B mouse). 
We observed abnormally high elevated levels of platelet desialylation in both patients with 
the p.V1316M mutation and the 2B mice. In vitro, we demonstrated that 2B p.V1316M/von 
Willebrand factor induced more desialylation of normal platelets than wild-type von 
Willebrand factor did. Furthermore, we found that N-glycans were desialylated and we 
identified αIIb and β3 as desialylation targets. Treatment of 2B mice with sialidase inhibitors 
(which correct platelet desialylation) was not associated with the recovery of a normal 
platelet count. Lastly, we demonstrated that a critical platelet desialylation threshold (not 
achieved in either 2B patients or 2B mice) was required to induce thrombocytopenia in vivo. 
In conclusion, in type 2B von Willebrand disease, platelet desialylation has a minor role and 
is not sufficient to mediate thrombocytopenia. 
 
 
 3
INTRODUCTION 
Type 2B von Willebrand disease (VWD) is characterized by gain-of-function mutations in the 
gene coding for von Willebrand factor (VWF), which enhance the factor’s ability to bind 
platelet glycoprotein Ibα (GPIbα). Patients with type 2B VWD display bleeding to a variable 
extent and, in some cases, thrombocytopenia. There are several underlying causes of 
thrombocytopenia described in type 2B VWD, including the incorporation of platelets bound 
to plasma VWF into circulating aggregates,1-3 and defective platelet production.4,5 In many 
cases multiple mechanisms may contribute to the development of thrombocytopenia and 
may lead to severe life-threatening bleedings. Identification of the causes of 
thrombocytopenia is crucial for the appropriate management of patients. A new and original 
concept relates to platelet desialylation a process in which terminal sialic acids are cleaved 
on the platelet surface and leads to accelerate platelet clearance and thrombocytopenia. 
Sialic acids are terminal sugar components of glycoprotein oligosaccharide chains. Platelet 
desialylation is involved for physiological platelet aging in vivo. Indeed, the removal of 
platelet sialic acid exposes β-galactose residues (considered to be senescence antigens), 
and facilitates platelet uptake by Kupffer cells in cooperation with hepatocytes via the hepatic 
asialoglycoprotein receptor.6,7 Over the past few decades, it has been shown that platelet 
desialylation is responsible for platelet clearance in many contexts, such as immune 
thrombocytopenia.8,9 Recently, Deng et al. described a new mechanism for platelet clearance 
mediated by active VWF bound to GPIbα.10 More specifically, the researchers demonstrated 
that a VWF/botrocetin complex and VWF from a patient carrying a p.V1316M mutation led to 
β-galactose exposure in vitro. On the basis of these observations, Deng et al. predicted that 
this β-galactose exposure might be responsible (at least in part) for thrombocytopenia in type 
2B VWD. However, this hypothesis had not previously been tested in vivo.  
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METHODS 
Patients. A total of 36 patients with type 2B VWD (from 17 unrelated families) and 35 healthy 
age- and sex-matched controls were enrolled. In accordance with the tenets of the 
Declaration of Helsinki, the study participants were informed about the anonymous use of 
their personal data, and gave their written, informed consent. The study was approved by the 
local investigational review board (Lille University Medical Center, Lille, France). The French 
National Reference Centre for Von Willebrand Disease database and biological resource 
center (plasma and DNA) were registered with the French National Data Protection Authority 
(reference: CNIL 1245379). Platelet counts and mean platelet volume (MPV) were measured 
with an automated analyzer (XN-10, Sysmex France). 
 
Mice. The type 2B VWD knock-in mouse model (p.V1316M) has been described 
elsewhere.11 Mice homozygous for the p.V1316M mutation are referred to hereafter as “2B 
mice”, and their control littermates are referred as wild-type (“WT”) mice. Platelet counts 
were determined with an automated analyzer (Scil Vet ABC Plus, Horiba Medical). Male and 
female mice were used indifferently. The study was approved by the local animal care and 
use committee (reference: APAFIS#1294-2015072816482568). 
 
Flow cytometry. Platelet surface β-galactose exposure was determined by using FITC-
conjugated Ricinus communis agglutinin I (RCA for platelet-rich plasma 12.5 μg/mL, for 
washed mouse platelets 5 μg/mL) and Erythrina cristagalli lectin (ECL, 10 μg/mL). Samples 
in which RCA or ECL was incubated with β-lactose12 (200 mM) were used as corresponding 
negative controls. Platelet surface α-2,3-sialylation on O-glycans was determined by using 
biotinylated Maackia amurensis lectin II7,13 (MALII, 10 μg/mL) and phycoerythrin (PE)-
streptavidin (10 μg/mL). Briefly, platelet-rich plasma or washed platelets (5 μL) were 
incubated with lectins for 30 min at room temperature in a final volume of 100 μL. The 
reaction was stopped with PBS (400 μL). In some experiments, washed murine platelets 
(100 μL, 105/μL) were treated with 10,000 U/mL of Peptide:N-glycosidase F (PNGase F) for 
18h at 37°C or treated with 100 μg/mL O-sialoglycoprotein endopeptidase (OSGE) for 30 min 
at 37°C. The platelets were washed and then stained with a lectin or an FITC-conjugated 
antibody against mouse GPIbα, GPVI or αIIbβ3. Surface neuraminidase-1 (NEU1) 
expression was measured with rabbit anti-NEU1 antibody (4 μg/mL) and detected with Alexa 
Fluor 488 secondary antibody (6 μg/mL). Lectin or antibody binding was determined using a 
flow cytometer (a BD Accuri system for mouse samples, and a Beckman Coulter Navios 
system for human samples). 
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Statistics. Statistical analyses were performed using Prism 6 for Mac software (version 6; 
GraphPad, Inc., San Diego, CA). If only two groups were compared, a Student’s t test was 
used. For 3 or more groups, a 1-way analysis of variance (ANOVA) and Dunnett’s post-test 
were used. Before performing these tests, a D’Agostino-Person normality test was used to 
determine whether data were normally distributed. Equality of variance was tested with an F 
test prior to Student’s t test or with Bartlett’s test prior to an ANOVA. Correlations were 
assessed by calculating Pearson’s coefficient r.  
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RESULTS  
Platelet desialylation in human and murine type 2B VWD in vivo 
To examine the putative link between platelet desialylation and thrombocytopenia in type 2B 
VWD, we assessed β-galactose exposure at the platelet surface (i.e. a marker of sialic acid 
removal from glycoproteins). We first analyzed the platelet count and the extent of platelet β-
galactose exposure (by measuring RCA binding) in 36 patients with type 2B VWD and 35 
healthy controls. The mean ± standard deviation (SD) platelet count was significant lower in 
the patient group (217 ± 70 x 103/μL) than in the control group (256 ± 47 x 103/μL ; p=0.012). 
The amount of β-galactose (measured as the mean ± SD fluorescence intensity, MFI, for 
RCA) was significant higher in the patient group (7.0 ± 2.6) than in the control group (5.5 ± 
2.3; p=0.011). The individual platelet counts were weakly correlated with levels of surface-
exposed β-galactose in patients with type 2B VWD (r2=0.113, p=0.048) but not correlated in 
controls (r2=0.095, p=0.092) (Figure 1A). Patients bearing the p.R1341Q mutation displayed 
a significantly lower mean platelet count and a significantly greater RCA MFI (Figure 1B-Ci). 
In contrast, the platelet count and RCA binding in patients bearing the p.R1306Q mutation 
did not differ significantly from the values observed for controls. Interestingly, patients 
carrying the severe p.V1316M mutation exhibited the lowest platelet count and the highest 
amount of β-galactose (2.1-fold more than controls) (Figure 1B-Ci). To take platelet size into 
account, we also measured the ratio between the RCA MFI and the MPV. The elevated level 
of RCA binding (relative to controls) was no longer observed for patients with the p.R1341Q 
mutation but was still observed for those bearing the p.V1316M mutation (Figure 3Cii).  
Given that the p.V1316M mutation in VWF was associated increased β-galactose exposure 
in our study (n = 2 patients) and also in vitro,10 we studied the possible role of desialylation in 
our recently engineered knock-in murine model of severe type 2B VWD (p.V1316M 
mutation). The murine disease mimics the human disease, and 2B mice display 
thrombocytopenia 4,11 (mean ± SD platelet count: 355 ± 104 x 103/μL), relative to WT mice 
(803 ± 159 x 103/μL). Platelets from 2B mice had a significantly greater amount of exposed 
β-galactose (MFI for RCA: 7093 ± 3156, n=67) than WT mice did (3154 ± 1098, n=61; 
p<0.001, Figure 1Di). After taking platelet size into account by measuring the ratio between 
the MFI for RCA to the MFI for CD41 (αIIb integrin), an (2-fold) elevation was still observed 
(RCA/CD41: 0.358 ± 0.181 for 2B mice, n=67; 0.179 ± 0.600 for WT mice, n=61; p<0.001) 
(Figure 1Dii). Thus, our results evidenced a link between the platelet count and platelet 
desialylation in type 2B VWD.  
 
2B VWF induces N-glycan-specific platelet desialylation  
With a view to highlighting a direct link between the p.V1316M mutation in VWF and 
desialylation, we incubated plasma from 2B mice (p.V1316M) with WT platelets. In contrast 
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to VWF-deficient or WT plasma, 2B plasma induced β-galactose exposure (with a 1.48 ± 
0.12-fold increase, Figure 2A) to the same extent as botrocetin treatment of WT plasma 
(Supplemental Figure 1), as previously described.10 We confirmed that p.V1316M/VWF (0.2 
μg/mL) induced desialylation (relative to WT/VWF) by incubating normal washed platelets 
with recombinant p.V1316M/VWF; we observed a 1.85 ± 0.15-fold relative increase (Figure 
2B). We confirmed this result with another lectin (ECL) that is specific for β-galactose (Figure 
2C). We then investigated how does gain-of-function VWF mediate platelet desialylation. 
Desialylation is due to the activity of neuraminidases NEU1, a sialidase catalyzing the 
removal of terminal sialic acids from sialyloconjugates. Relative to WT/VWF, p.V1316M/VWF 
treatment was able to induce the translocation of NEU1 to the platelet surface (Figure 2D). 
Platelet glycoproteins are commonly modified by complex carbohydrates including N-linked 
glycans (N-glycans) and mucin-type O-linked glycans (O-glycans).7,14 Both N- and O-glycans 
are commonly “capped” by sialic acids. We next looked at whether the desialylation induced 
by the p.V1316M/VWF occurred on O-glycans and/or N-glycans. To this end, we used MALII 
lectin which recognizes α-2,3-sialylation on O-glycans,7,13 and a recent study found that the 
absence of O-glycans (in C1galt1-/- mice) reduced MALII binding but did not change RCA 
binding.7 We first confirmed the specificity of MALII by using desialylated platelets showing a 
decrease of the MALII binding, as expected (Supplemental Figure 2). We found that 
p.V1316M/VWF did not change MALII binding to platelets, relative to WT/VWF (Figure 2E), 
suggesting that desialylation was not likely to be on O-glycans. We next looked at whether 
the desialylation induced by the 2B VWF occurred on N-glycans by using PNGase F - the 
most effective enzymatic method for removing N-linked oligosaccharides from glycoproteins. 
We first characterized the effect of PNGase F treatment on RCA, ECL and MALII binding on 
platelets. PNGase F treatment reduced the binding of RCA (to 40 ± 4% of the control value, 
Figure 2F) and ECL (to 50 ± 10%, data not shown) to WT platelets but not that of MALII. 
Given that RCA and ECL were sensitive to PNGase F, the platelets were then incubated with 
WT or p.V1316M/VWF to induce desialylation and were then treated (or not) with PNGase F 
during 18h. Platelet desialylation was still observed after 18h of incubation in the absence of 
PNGase F (RCA ratio: 0.97 ± 0.04 for WT, and 1.49 ± 0.13 for 2B; p<0.01) (Figure 2G). 
Strikingly, removal of N-glycans after p.V1316M/VWF treatment was associated with much 
lower RCA binding (Figure 2G, p<0.001). Indeed, RCA binding in the presence of WT or 2B 
VWF was similar after PNGase F treatment (RCA ratio: 0.62 ± 0.07 for WT, and 0.72 ± 0.06 
for 2B). Taken as a whole, our results demonstrated for the first time that the p.V1316M 
mutation in VWF induces N-glycan-specific platelet desialylation. 
 
2B VWF induces αIIb and β3 desialylation  
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Many platelet glycoprotein and surface receptors contain sialic acid. GPIbα contains the 
highest levels, followed by integrin β3, integrin αIIb, GPV and GPVI/GPIbβ/GPIX, for the 
main receptors.7 We first investigated whether GPIbα and GPVI were desialylated-targets by 
the p.V1316M/VWF. We found that treatment with OSGE, which removes GPIbα and, to 
some extent, GPVI but not αIIbβ3 did not change RCA and ECL binding (Figure 3A), 
suggesting that the desialylation induced by p.V1316M/VWF did not take place on GPIbα 
and GPVI. We then confirmed that p.V1316M/VWF did not induce GPIbα and GPVI 
desialylation by performing RCA pull-down experiments followed by western blotting (Figure 
3B). This data confirms our results and rule out mouse GPIbα and GPVI as a specific platelet 
desialylation targets by p.V1316M/VWF. Taken as a whole our present results reveal the 
existence of desialylation of platelet proteins other than GPIbα and GPVI.7,15 The next 
candidates were the integrins αIIb and β3 carrying sialic acid both on N- and O-glycans.7,15 
We performed RCA pull-down experiments by incubating normal washed platelets with 
recombinant WT/VWF or p.V1316M/VWF. Our results demonstrated that p.V1316M/VWF 
induced αIIb and β3 desialylation. Indeed, we observed a 1.90 ± 0.17-fold relative increase 
for αIIb and a 2.02 ± 0.36-fold relative increase for β3 compared to WT/VWF (Figure 3C). 
Taken as a whole, our results demonstrated for the first time that the p.V1316M mutation in 
VWF induces αIIb and β3 desialylation. 
 
Thrombocytopenia in type 2B mice is independent of platelet desialylation 
Since desialylation is mediated by sialidases, we next treated 2B and WT mice with two 
sialidase inhibitors (DANA or oseltamivir phosphate) or Hank's balanced salt solution as a 
control. Treatment with each inhibitor was associated with significantly lower platelet 
desialylation in vivo (as measured by RCA binding) in 2B mice but not in WT mice (Figure 
4A-B). After 6h of treatment, the level of RCA binding was much the same as in the WT mice 
(Figure 4A-B). Surprisingly, the platelet counts remained low and unchanged in 2B mice for 
up to 7 days after the infusion (168h, Figure 4A). Our observation was especially surprising 
because both sialidase inhibitors have been reported to correct platelet counts in immune 
thrombocytopenia, with a desialylation profile after a single administration of a lower dose 
than that used in our experiments.9,16 Our findings indicate for the first time that the level of 
desialylation observed in type 2B VWD mice has only a minor role in platelet clearance or is 
not sufficient to induce thrombocytopenia. This lack of effect might be attributable to the type 
of desialylation. Although elevated platelet clearance has been reported in mice lacking N-
glycan sialylation,17 a recent study provided insights into the essential role of O-glycan 
sialylation in platelet clearance.7 Furthermore, it has been reported that both mouse and 
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human platelets contain high levels of O-glycans, with more sialic acids on the latter than on 
N-glycans. 7,18 
 
Threshold of platelet desialylation and thrombocytopenia 
We then looked at whether the sialidase inhibitors’ apparent lack of effect in 2B mice was 
due to a threshold effect, i.e. whether a minimum level of desialylation was required to 
significantly affect platelet count. Hence, WT mice were treated with various concentrations 
of neuraminidase, and the desialylation efficiency was monitored by RCA binding (Figure 
5A). We observed a clear relationship between desialylation and the fall in the platelet count 
(Figure 5A). Importantly, the platelet count was not affected when the RCA ratio was around 
2 or less (Figure 5B). We observed a strong and inverse correlation between the platelet 
count and RCA ratio (r2=0.95) and the circulating platelet count was about half the control 
value, corresponding to a RCA ratio of 10 (Figure 5C). This strongly indicates that the RCA 
ratio observed in patients and mice with the severe p.V1316M mutation (giving 2.1-fold and 
2-fold differences, respectively) does not explain the low platelet count.  
To investigate the threshold of platelelet desialylation linked or not to thrombocytopenia, 
reference interval has to be determined in the WT population. With the parametric approach, 
the central 95% boundaries are specified by the mean ± 2SD, if the data follow a Gaussian 
(normal) distribution. After having confirmed if our values come from a Gaussian distribution 
by using a D’Agostino-Pearson omnibus normality, we calculated, in WT mice population, a 
mean platelet count of 803 x 103 platelets/μL with SD=159 (n=129) and mean- 2SD of 485 x 
103 platelets/μL. Under this value of platelet count, mice could be considered as 
thrombocytopenic. Based on graph Figure 5C, a minimal platelet count of 485 x 103 
platelets/μL corresponds to a RCA ratio of 6.2. Under this threshold, the thrombocytopenia 
observed is likely to be independent of desialylation, and above this threshold, the 
thrombocytopenia is likely to be desialylation dependent.  
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DISCUSSION 
In the present study, we tested the hypothesis whereby accelerated platelet clearance (and 
thus thrombocytopenia) in type 2B von Willebrand disease is caused by desialylation. 
Indeed, Deng et al. recently proposed a novel original mechanism of platelet clearance 
mediated by active von Willebrand factor.10 More specifically, authors demonstrated that type 
2B VWF led to platelet desialylation, and predicted that this process might be responsible (at 
least in part) for the thrombocytopenia observed in type 2B VWD. This hypothesis has yet to 
be tested in vivo. 
We had access to blood samples from a cohort of 36 patients with three different mutations 
(p.R1341Q, p.R1306Q, and the severe p.V1316M) and from 35 healthy controls. We also 
studied our novel mouse model bearing a point mutation (p.V1316M) in the endogenous Vwf 
gene; we recently validated this mouse as a relevant model of type 2B VWD.4,11  
Our present results indicated that even though the level of desialylation was abnormally high 
in both human and murine models, it was not sufficient to mediate thrombocytopenia. Indeed, 
treatments of 2B mice with the sialidase inhibitors oseltamivir (Tamiflu®) and DANA did not 
correct the thrombocytopenia. 
How does gain-of-function VWF mediate platelet desialylation? In platelets, the sialidase 
activity is due to the activity of neuraminidases. Neuraminidase 1 (NEU1) is a lysosomal 
sialidase catalysing the removal of terminal sialic acids from sialyloconjugates. Furthermore, 
this NEU1 was found to be abundant in the granules of permeabilized platelets, and was able 
to translocate to the platelet membrane.9 Plasma-membrane-bound NEU1 modulates a 
plethora of receptors by desialylation. At the plasma membrane, NEU1 has been shown to 
be required for signal transduction, and recent results have provided new insights in the 
molecular organization of membrane-bound NEU1. Indeed, the protein has two potential 
transmembrane domains that may anchor NEU1 to the membrane and control its 
dimerization and sialidase activity.19 It has been reported that the sialidase NEU1 is involved 
in platelet desialylation.20 In the present study, we found a translocation of NEU1 at the 
platelet surface after stimulation with the p.V1316M/VWF, suggesting a reorganization of 
platelet membrane. However, neither platelet activation nor P-selectin exposure were found 
after p.V1316M/VWF treatment (data not shown). This results are in agreement with previous 
reports. Indeed, patients with type 2B VWD have a bleeding tendency that is linked to the 
loss of VWF multimers and platelet dysfunction.21 Platelet functions were diminished due to 
the inhibition of integrin αIIbβ3 and of the small GTPase Rap1 by VWF/p.V1316M following 
exposure to platelet agonists. These data indicate that the type 2B mutation p.V1316M is 
associated with severe thrombocytopathy, and that the addition of 2B/VWF leads to platelet 
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inhibition rather than activation. The mode of action of NEU1 and its localization and also the 
potential link between NEU1 activation and platelet dysfunction require further investigations. 
We determined which mode of desialylation was induced by type 2B VWF. We studied the 
binding of MALII lectin (which reportedly binds to α-2,3-sialylation on O-glycans) in the light 
of a recent study showing that O-glycan desialylation is important for platelet clearance.7 The 
level of MALII lectin binding did not change in the presence of type 2B/VWF (relative to 
WT/VWF). We next determined whether the desialylation induced by the 2B/VWF occurred 
on N-glycans. After the desialylation induced by 2B/VWF, we removed N-glycans by 
incubation with PNGase F. This treatment reduced RCA and ECL binding but not MALII 
binding. Taken as a whole, our results demonstrate for the first time that the p.V1316M 
mutation of VWF specifically induces desialylation on platelet N-glycans. One important 
question was the identification of targets. We ruled out desialylation of GPIbα and GPVI. 
Indeed, we found that treatment with O-sialoglycoprotein endopeptidase (OSGE, which 
removes GPIbα and, partially, GPVI) did not change RCA and ECL binding - suggesting that 
the desialylation induced by 2B/VWF did not occur on GPIbα and GPVI. Interestingly, 
assessment of baseline desialylation of GPIbα-/- platelets (using RCA) revealed an 
unexpected elevation in desialylation, relative to WT platelets.15 Furthermore, treatment of 
GPIbα-/- platelets with neuraminidase was associated with a 10-fold relative increase in RCA 
binding.15 On the other hand, mouse GPIbα contains the highest levels of sialic acid on O-
glycans but no sialic acid was predicted on N-glycans.7 The next obvious candidates were 
the integrins αIIb and β3 carrying sialic acid both on N- and O-glycans and in mouse 
platelets the integrins αIIbβ3 is one of the most sialylated glycoprotein on N-glycans. 7 We 
performed RCA pull-down and our results demonstrated for the first time that 
p.V1316M/VWF induced αIIb and β3 desialylation. Nowadays, no study demonstrated that 
the integrin αIIbβ3 is a target of desialylation. 
We then looked at whether a minimum level of desialylation was required to significantly 
affect platelet count. To investigate the threshold of platelelet desialylation linked or not to 
thrombocytopenia, reference interval has been determined in the WT population and the 
RCA value corresponding to the low platelet count was calculated. We found a RCA value of 
6.2 suggesting that under this threshold, the thrombocytopenia observed is likely to be 
independent of desialylation, and above this threshold, the thrombocytopenia is likely to be 
desialylation dependent. However, this critical platelet desialylation threshold requires to 
induce thrombocytopenia in vivo was not achieved in either 2B patients or 2B mice with the 
p.V1316M mutation (giving 2.1-fold and 2-fold differences, respectively) and so does not 
explain the low platelet count. 
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To go further, the weak observed correlation between RCA binding and the platelet count in 
patients (Figure 1A) suggests that under stressful conditions where thrombocytopenia may 
be exacerbated (e.g. pregnancy or surgery), desialylation could be associated with other 
mechanisms involved in thrombocytopenia, such as platelet production defects in 
megakaryocytes,4 and the accelerated uptake of VWF/platelet complexes in macrophages.1 
However, this speculative point requires further investigation. 
In conclusion, elevated levels of desialylation are observed in patients with type 2B VWD and 
mice carrying the p.V1316M mutation. The desialylation primarily concerns N-glycans and 
does not involve GPIbα or GPVI but involved αIIb and β3 integrins. Although desialylation 
was observed under baseline conditions, it does not appear to be important contributor to 
thrombocytopenia in type 2B VWD.  
 13
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Figure legends 
Figure 1: Platelet desialylation in human and murine type 2B VWD in vivo 
A) Analysis of the correlation between RCA binding and the platelet count in patients with 
type 2B VWD (n=36, left panel: r2=0.113, p=0.048) and healthy controls (n=35, right panel: 
r2=0.095, p=0.092). Distribution of platelet counts (B) and RCA MFI (Ci) or RCA/MPV (Cii) 
values in healthy controls and in patients with type 2B VWD, as a function of the mutation in 
the VWF A1 domain (p.R1341Q, n=30, p.R1306Q, n=4, p.V1316M, n=2). A one-way ANOVA 
was followed by Dunnett’s test; *p<0.05. D) Distribution of RCA MFI (Di) or RCA/CD41 (Dii) 
values in WT (n=61) and 2B mice (n=67) (unpaired Student’s t test; ***p<0.001).  
 
Figure 2: Platelet desialylation by 2B VWF in vitro occurs on N-glycans 
A) A histogram of RCA lectin binding on WT mouse platelets in PRP treated with VWF-
deficient plasma (VWF-dp), WT plasma or 2B plasma. The fold change in each experiment 
was calculated relative to the binding obtained with VWF-deficient plasma, set to 1. The 
mean ± SD values (n=3 experiments) were compared using a one-way ANOVA and 
Dunnett’s post-test. **p<0.01. B) A histogram of RCA lectin binding to washed WT mouse 
platelets treated with WT or 2B mouse VWF (p.V1316M). C) Histograms of RCA and ECL 
binding (for β-galactose exposure) on washed WT mouse platelets treated with 0.2 μg/mL 
WT or 2B mouse VWF. The fold change in each experiment was calculated relative to the 
baseline value (in the absence of VWF), set to 1. The mean ± SD values (n=4 experiments) 
were compared using a one-way ANOVA and Dunnett’s post-test, **p<0.01). D) Flow 
cytometric analysis of NEU1 expression on washed WT mouse platelets treated with 0.2 
μg/mL WT or 2B mouse VWF. *p<0.05. E) Histograms of MALII lectin binding (for α-2,3-
linked sialic acids on O-glycans) on washed WT mouse platelets treated with 0.2 μg/mL WT 
or 2B mouse VWF. F) Flow cytometric analysis of WT platelets after treatment (or not) with 
PNGase F and staining with RCA and MALII lectin. The data are representative of 3 
independent experiments. G) A histogram of RCA binding on washed WT mouse platelets 
treated with 0.2 μg/mL WT or 2B VWF. Platelets were then treated (or not) with PNGase F. 
The mean ± SD values (n=3 experiments) were compared using a one-way ANOVA and 
Dunnett’s post-test. ***p<0.001.  
 
Figure 3: Type 2B VWF induces desialylation of the integrin αIIbβ3 
A) Flow-cytometric analysis of WT platelets after being stained for GPIbα, GPVI, αIIbβ3, RCA 
and ECL with or without (w/o) OSGE treatment. Graphs are representative of 3 independent 
experiments. 
B) RCA pull-down and western-blot. Washed WT mouse platelets were treated with WT or 
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2B mouse VWF during 1 hour and then lyzed and prepared to RCA pull-down. Samples were 
subjected to western blot to analyze: B) GPIbα and GPVI, C) αIIb and β3. A histogram of 
αIIb and β3 in the pull-down expressed in desialylated form (from pull-down) / total form 
(from lysate). The mean ± SD values (n=3 experiments) were compared using a one-way 
ANOVA and Dunnett’s post-test, *p<0.05; ***p<0.001).  
 
Figure 4: Effect of platelet desialylation on the platelet count 
A) Platelet RCA MFI (left) and whole-blood platelet counts (right) in 2B (red line) and WT 
(black line) mice were measured at the indicated time points before and after treatment with 
a sialidase inhibitor (DANA or oseltamivir phosphate) or HBSS as a control (2B: n=4 mice for 
the control, n=11 mice for DANA, n=6 mice for oseltamivir phosphate, WT: n=4 mice for the 
control, n=3 mice for DANA, n=3 mice for oseltamivir phosphate). The mean ± SD values 
were compared using a one-way ANOVA and Dunnett’s post-test, *p<0.05, **p<0.01, in a 
pre-/post-treatment comparison. B) A histogram of RCA lectin binding (top panel) and the 
platelet count (bottom panel) before and 6 hours after the injection of the drugs into WT and 
2B mice. **p<0.01. 
 
Figure 5: A threshold of platelet desialylation is required to affect the platelet count 
A) Relative whole-blood platelet counts (dashed red line) and platelet RCA MFI (solid black 
line) in WT mice 1 hour after in vivo treatment with neuraminidase (n=3 mice for each 
concentration, values are quoted as the mean ± SD). The increase in RCA binding was 
calculated for each mouse as the ratio between the RCA MFI after treatment and the RCA 
MFI before treatment. B) The panel focuses on the stability of the relative platelet count and 
the increase in RCA binding after treatment with low doses of neuraminidase (0, 2.5 and 5 
mU/g of body weight). C) The correlation between the relative platelet count and RCA 
binding after neuraminidase treatment (r2=0.95 in a linear regression).  
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Reagents  
 
 
Antibodies 
 
 
Methods 
 
Recombinant mVWF/p.V1316M. Baby hamster kidney cells were transfected with pNUT-
mouse VWF and pNUT-mouse VWF/p.V1316M encoding mouse VWF and mouse 
VWF/p.V1316M, as previously described.1 Serum-free-conditioned medium was collected, 
and VWF antigen levels were quantified, taking normal pooled human plasma as a reference 
(100%).  
 
Desialylation by VWF. Citrated plasma from WT or 2B mice was mixed 9:1 (v/v) with 
citrated platelet-rich plasma from WT mice. Washed platelets (prepared as previously 
described)2 were incubated in the presence of WT or 2B recombinant murine VWF 
Name Vendor or Source Catalog # 
Ricinus communis agglutinin I (RCA) Vector Labs FL-1081 
Erythrina cristagalli (ECL) Vector Labs FL-1141 
Biotinylated Maackia amurensis lectin II (MALII) Vector Labs B-1265 
β-lactose Sigma-Aldrich L3750 
α2-3,6,8 neuraminidase from C. perfringens Sigma-Aldrich N-3001 
PE-streptavidin Calbiochem 189737 
PNGase F New England Biolabs P0704 
O-sialoglycoprotein endopeptidase (OSGE) Cedarlane CLE100 
DANA (N-Acetyl-2,3-dehydro-2-deoxyneuraminic Acid) Santa Cruz SC-215433A 
Oseltamivir phosphate Selleckchem S2597 
Target antigen Vendor or Source Catalog # 
FITC-rat anti-mouse GPIbα mAb (clone XiaG5) Emfret Analytics M040-1 
FITC-rat anti-mouse GPVI  mAb (clone JAQ1) Emfret Analytics M011-1 
FITC-rat anti-mouse integrin αIIbβ3 mAb (clone Leo.H4) Emfret Analytics  M021-1 
FITC-rat IgG negative control Emfret Analytics P190-1 
FITC-rat anti-mouse CD41 mAb (clone MWReg30) BD Pharmingen 553848 
FITC-rat IgG negative control BD Pharmingen 553924 
Neu1 (clone H-300) Santa Cruz SC-32936 
Purified rat anti-mouse GPIbα (clones XiaG5/XiaG7) Emfret Analytics M040-0/M042-0 
Purified rat anti-mouse integrin αIIb (clone 386627) R&D MAB 4118 
Purified rat anti-mouse integrin β3 (clone Luc.A5) Emfret Analytics M030-0 
Purified rat anti-mouse GPVI (clone JAQ1) Emfret Analytics M011-0 
Alex fluor 488 goat anti-rabbit secondary antibody Invitrogen A11008 
2 
	
(p.V1316M). All samples were incubated for 1 hour at 37°C without stirring. 
RCA pull-down. Washed platelet (500 µL at 3.108/mL) were lyzed (NaCl 0.15 M, HEPES 5 
mM, NP40 1%, octylglucopyranoside 0.1%, SDS 0.1%, EDTA 1 mM, cantharidine 10 µM, 5 
µg/ml leupeptin, 10 µg/ml aprotinin) and centrifuged 14 000g during 20 min. Biotinylated-RCA 
(5 µg/mL) was added to the supernatant and incubated during 1h at 4°C while rotating. Then, 
samples were incubated for 1h with streptavidin magnetic beads at room temperature while 
rotating. The beads were then washed and proteins were eluted with SDS sample buffer. 
 
Western-blot. Samples were separated by 4-12% SDS-PAGE, and immunoblotted with anti-
GPIbα antibodies (mix of clones XiaG5/XiaG7, 1/100), GPVI (1/100), αIIb (1/1000), β3 
(1/200). Immunoreactive bands were visualized using Enhanced Chemiluminescence 
Detection Reagents (Pierce). Images of the chemiluminescent signal were captured using 
G:BOX Chemi XT16 Image Systems and quantified using Gene Tools version 4.0.0.0 
(Syngene). 
 
In vivo sialidase inhibitors. The neuraminidase inhibitors N-acetyl-2,3-dehydro-2-
deoxyneuraminic acid (DANA, 0.1 mg/g total body weight) and oseltamivir phosphate (0.025 
mg/g total body weight) were respectively injected intraperitoneally and intravenously into 2B 
and WT mice. An injection of Hank's balanced salt solution was used as a control. After 6, 
24, 48, 96, and 168 h (i.e. up to 7 days), the mice were bled, and the platelet count and RCA 
binding were measured. 
 
In vivo desialylation. WT mice received an intravenous injection of C. perfringens α2-3,6,8 
neuraminidase. The platelet count and RCA binding were measured after 1 hour. 
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Supplemental data 
 
 
Supplemental Figure 1: Histogram of RCA lectin binding on WT mouse platelets in the 
presence of VWF-deficient plasma (KO VWF), WT plasma, 2B plasma or WT plasma in the 
presence of botrocetin (5 µg/mL). The fold increase in each experiment was calculated with 
the VWF-deficient plasma as set as 1. (Mean ± SD, n=3, One-way Anova followed by 
Dunnett’s test. **p<0.01.  
 
 
 
 
 
Supplemental Figure 2: Histogram of MFI of MALII/streptavidin (left) and RCA (right) lectin 
binding on WT mouse platelets treated or not with neuraminidase (0.05 U/mL).  
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